- Trials with a EudraCT protocol (66)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
66 result(s) found for: Enoxaparin sodium.
Displaying page 1 of 4.
EudraCT Number: 2020-001823-15 | Sponsor Protocol Number: 20CH089 | Start Date*: 2020-04-28 | ||||||||||||||||
Sponsor Name:CHU de Saint Etienne | ||||||||||||||||||
Full Title: Evaluation of the concentration-effect relationship of enoxaparin for thromboembolic prevention in COVID-19 resuscitation patients. COV-ENOX study | ||||||||||||||||||
Medical condition: covid-19 | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000099-12 | Sponsor Protocol Number: APHP180617 | Start Date*: 2021-10-12 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS | |||||||||||||
Full Title: Dose-adjustment of enoxaparin by a bayesian pharmacological approach in pediatric renal transplant recipients | |||||||||||||
Medical condition: Allograft vascular thrombosis | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002259-20 | Sponsor Protocol Number: CASUAL_ECMO | Start Date*: 2023-08-17 |
Sponsor Name:Medical University of Vienna | ||
Full Title: A three-arm randomized controlled non-inferiority pilot study Comparing Anticoagulation Strategies using Unfractionated heparin, Argatroban and Low-molecular-weight heparin for Extracorporeal Memb... | ||
Medical condition: patients with indication for extracorporeal membrane oxygenation therapy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2004-001128-19 | Sponsor Protocol Number: CV185-010 | Start Date*: 2004-11-02 |
Sponsor Name:Bristol-Myers Squibb International Corporation | ||
Full Title: A Phase 2 Randomized, Double Blinded (BMS-562247 and enoxaparin), Active-Controlled (enoxaparin and warfarin), Parallel-Arm, Dose Response Study of the Oral Factor Xa Inhibitor BMS-562247 in Subjec... | ||
Medical condition: Prevention of asymptomatic and symptomatic deep vein thrombosis (DVT) and non-fatal pulmonary embolism (PE) in subjects undergoing knee replacement surgery. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-003148-21 | Sponsor Protocol Number: DU176b-F-E308 | Start Date*: 2014-06-17 | |||||||||||
Sponsor Name:Daiichi Sankyo Development Ltd | |||||||||||||
Full Title: A prospective, randomised, open-label, blinded endpoint evaluation (PROBE) parallel group study comparing edoxaban (DU-176b) with enoxaparin/warfarin followed by warfarin alone in subjects undergoi... | |||||||||||||
Medical condition: Stroke and thromboembolism prevention in patients with non-valvular atrial fibrillation (NVAF) undergoing planned electrical cardioversion. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) BE (Completed) DE (Completed) GB (Completed) HU (Completed) IT (Completed) DK (Completed) ES (Completed) AT (Completed) CZ (Completed) NL (Completed) RO (Completed) BG (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-007867-25 | Sponsor Protocol Number: CV185-056 | Start Date*: 2008-08-26 | ||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||
Full Title: A Safety and Efficacy Trial Evaluating the Use of Apixaban in the Treatment of Symptomatic Deep Vein Thrombosis and Pulmonary Embolism. Revised Protocol Number 02 incorporating Amendment(s) 04... | ||||||||||||||||||
Medical condition: Venous Thromboembolism (VTE) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) FR (Completed) AT (Completed) HU (Completed) ES (Completed) PT (Completed) DK (Completed) CZ (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-004614-14 | Sponsor Protocol Number: BAY 59-7939/12839 | Start Date*: 2007-12-05 | |||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||
Full Title: MAGELLaN - Multicenter, rAndomized, parallel Group Efficacy and safety study for the prevention of venous thromboembolism in hospitalized medically iLL patients comparing rivaroxabAN with enoxaparin | |||||||||||||
Medical condition: Prevention of venous thromboembolism in patients who have been hospitalized for a medical illness | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DE (Completed) FR (Completed) DK (Completed) LT (Completed) GB (Completed) BE (Completed) AT (Completed) NL (Completed) ES (Completed) GR (Completed) PT (Completed) SI (Completed) SK (Completed) CZ (Completed) IT (Completed) PL (Completed) LV (Completed) FI (Completed) HU (Completed) EE (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003125-39 | Sponsor Protocol Number: TRI-08892 | Start Date*: 2020-10-12 |
Sponsor Name:Thrombosis Research Institute | ||
Full Title: Early thromboprophylaxis in COVID-19 (ETHIC trial): an open label, randomized phase IIIb trial of community-based prophylactic low-molecular-weight heparin (LMWH) versus standard of care (no enoxap... | ||
Medical condition: Confirmed diagnosis of SARS-CoV-2 with symptomatic COVID-19 infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2020-005624-10 | Sponsor Protocol Number: OVID-trial | Start Date*: 2021-05-06 | ||||||||||||||||
Sponsor Name:University Hospital Zurich | ||||||||||||||||||
Full Title: ENOXAPARIN FOR PRIMARY THROMBOPROPHYLAXIS IN AMBULATORY PATIENTS WITH CORONAVIRUS: THE MULTICENTER RANDOMIZED CONTROLLED OVID TRIAL | ||||||||||||||||||
Medical condition: Patients diagnosed with COVID-19, a novel viral disease characterized by severe systemic, pulmonary, and vessel inflammation and coagulation activation. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000315-76 | Sponsor Protocol Number: 1375_RCF_MAC | Start Date*: 2021-12-06 | |||||||||||
Sponsor Name:Centro Hospitalar Universitário de Lisboa Central, EPE | |||||||||||||
Full Title: Low molecular weight heparin in the treatment of early fetal growth restriction | |||||||||||||
Medical condition: Early fetal growth restriction | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: PT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-003746-15 | Sponsor Protocol Number: 259-4-111IIT-ARX0257 | Start Date*: 2008-03-27 | |||||||||||
Sponsor Name:Ammerland-Klinik Westerstede | |||||||||||||
Full Title: prospective randomized open study on the comparison of fondaparinux with the low-molecular-weight heparin enoxaparin in patients undergoing femoro-distal venous bypass operation | |||||||||||||
Medical condition: Patients with underlying peripheral occlusive vascular disease undergoing bypass surgery | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002681-31 | Sponsor Protocol Number: BAY1213790/17664 | Start Date*: 2017-07-13 | |||||||||||
Sponsor Name:Bayer AG | |||||||||||||
Full Title: A randomized, active-comparator-controlled, multicenter study to assess the safety and efficacy of different doses of BAY 1213790 for the prevention of venous thromboembolism in patients undergoing... | |||||||||||||
Medical condition: Prevention of venous thromboembolism | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) LT (Completed) CZ (Completed) DE (Completed) LV (Completed) BG (Completed) PL (Completed) GR (Completed) PT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-002381-10 | Sponsor Protocol Number: 20051111 | Start Date*: 2005-08-18 |
Sponsor Name:Dept anaesthesiology and intensive care | ||
Full Title: Evaluation of the optimal dose of prophylactic anticoagulation with low-molecular-weight heparine administered subcutaneously to critically ill patients | ||
Medical condition: critically ill patients with sepsis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-003122-88 | Sponsor Protocol Number: SELK2-00005 | Start Date*: 2019-01-21 | |||||||||||
Sponsor Name:Tetherex Pharmaceuticals Corporation | |||||||||||||
Full Title: A Phase 2, Randomized, Active Comparator-Controlled, Open-Label, Adaptive Design Study to Assess the Safety and Efficacy of Intravenously-Administered SelK2 in Patients Undergoing Total Knee Arthro... | |||||||||||||
Medical condition: Venous thromboembolism occurring in patients undergoing total knee replacement arthroplasty | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) BG (Completed) LT (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014290-40 | Sponsor Protocol Number: DU176b-D-U305 | Start Date*: 2010-02-10 | ||||||||||||||||
Sponsor Name:Daiichi Sankyo Development Limited | ||||||||||||||||||
Full Title: A phase 3, randomized, double-blind, double-dummy, parallel-group, multi-center, multi-national study for the evaluation of efficacy and safety of (LMW) heparin/edoxaban versus (LMW) heparin/warfar... | ||||||||||||||||||
Medical condition: Reduction of the risk of symptomatic recurrent venous thromboembolic complications in patients with acute symptomatic deep vein thrombosis (DVT) and/or pulmonary embolism (PE) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) HU (Completed) DE (Completed) SE (Completed) FR (Completed) EE (Completed) BE (Completed) AT (Completed) ES (Completed) DK (Completed) CZ (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-000255-13 | Sponsor Protocol Number: 11-019 | Start Date*: 2012-06-20 | |||||||||||
Sponsor Name:Portola Pharmaceuticals, Inc. | |||||||||||||
Full Title: Multicenter, Randomized, Active-Controlled Efficacy And Safety Study Comparing Extended Duration Betrixaban With Standard Of Care Enoxaparin For The Prevention Of Venous Thromboembolism In Acute Me... | |||||||||||||
Medical condition: Prophylaxis of venous thromboembolism | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) LV (Completed) DE (Completed) ES (Completed) GB (Completed) PL (Completed) LT (Completed) AT (Completed) DK (Completed) CZ (Completed) BG (Completed) IT (Completed) FI (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-002161-39 | Sponsor Protocol Number: CV185-034 | Start Date*: 2006-12-05 |
Sponsor Name:Bristol-Myers Squibb International Corporation | ||
Full Title: A Phase 3 Randomized, Double-Blind, Active-Controlled (Enoxaparin), Parallel Group, Multi-Center Study to Evaluate the Safety and Efficacy of Oral Apixaban in Subjects Undergoing Elective Total Kne... | ||
Medical condition: Subjects undergoing elective total knee replacement surgery | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) SE (Completed) HU (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-003674-96 | Sponsor Protocol Number: CV185-036 | Start Date*: 2007-07-27 | |||||||||||||||||||||
Sponsor Name:Bristol Myers Squibb | |||||||||||||||||||||||
Full Title: A Phase 3 Randomized, Double-blind, Parallel-group, Multi-center Study of the Safety and Efficacy of Apixaban for Prophylaxis of Venous Thromboembolism in Acutely Ill Medical Subjects During and Fo... | |||||||||||||||||||||||
Medical condition: Total Venous thromboembolism (VTE), defined as the combination of fatal or nonfatal pulmonary embolism, symptomatic deep vein thrombosis (DVT), and asymptomatic proximal DVT. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: BE (Completed) SE (Completed) NL (Completed) CZ (Completed) AT (Completed) FR (Completed) DK (Completed) HU (Completed) DE (Completed) IT (Completed) GB (Completed) ES (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-006896-19 | Sponsor Protocol Number: CV185-047 | Start Date*: 2007-09-06 | |||||||||||||||||||||
Sponsor Name:Bristol Myers Squibb International Corporation | |||||||||||||||||||||||
Full Title: A Phase 3, Randomized, Double-blind, Active-controlled (Enoxaparin 40 mg QD), Parallel-group, Multi-center Study to Evaluate the Safety and Efficacy of Apixaban in Subjects Undergoing Elective Tota... | |||||||||||||||||||||||
Medical condition: Venous Thromboembolic Events | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) ES (Completed) NL (Completed) AT (Completed) BE (Completed) FR (Completed) HU (Completed) SE (Completed) IT (Completed) CZ (Completed) DK (Completed) DE (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-004368-23 | Sponsor Protocol Number: 20121005 | Start Date*: 2012-11-02 | |||||||||||
Sponsor Name:Odense University Hospital | |||||||||||||
Full Title: Feasible strategy for preventing blood clots in critically ill patients with acute kidney Injury | |||||||||||||
Medical condition: venous thromboembolism | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
